Please login to the form below

Not currently logged in
Email:
Password:

EC approves GSK's Tyverb for breast cancer

The European Commission (EC) has approved an additional use of GlaxoSmithKline's (GSK) Tyverb (lapatinib) as a treatment for breast cancer

The European Commission (EC) has approved an additional use of GlaxoSmithKline's (GSK) Tyverb (lapatinib), in combination with an aromatase inhibitor, as a treatment for post-menopausal women with hormone receptor-positive, HER2 over-expressing metastatic breast cancer and for whom chemotherapy is currently not intended.

The approval follows a positive recommendation by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) in February 2010.

According to a consensus forecast compiled by Thomson Reuters, sales of Tyverb in the US (where the drug is sold as Tykerb), are expected to reach around $375m in 2014.

Earlier this month, draft guidance issued by the UK's National Institute for Health and Clinical Excellence (NICE), recommended against the use of Tyverb outside of clinical trials. 

In the US, the Food and Drug Administration (FDA) approved the expanded use of Tyverb in combination with Novartis' Femara (letrozole)  - an aromatase inhibitor, in February 2010.

24th June 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

World Mental Health Day 2019: Employment and Mental Illness
Mednet Group's white paper with a focus on navigating the world of work is available online in aid of World Mental Health Day 2019....
Changing direction
Changing direction: adapting to a rapidly-evolving environment
Chris Ross examines why creative partnerships could be key to commercial success in today’s healthcare marketplace...
customer journey
Understanding the patient journey
What we can learn from customer service...

Infographics